Media coverage about ConforMIS (NASDAQ:CFMS) has been trending somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ConforMIS earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 47.1858561808578 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern’s rankings:
- ConforMIS Inc (CFMS) Expected to Announce Quarterly Sales of $19.26 Million (americanbankingnews.com)
- Brokerages Expect ConforMIS Inc (CFMS) to Announce -$0.20 Earnings Per Share (americanbankingnews.com)
- ConforMIS Inc (CFMS) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Conformis posts Q2 earnings, launches 3D-printed hip system (massdevice.com)
A number of equities research analysts have issued reports on CFMS shares. Zacks Investment Research cut ConforMIS from a “hold” rating to a “sell” rating in a research report on Wednesday, April 18th. BTIG Research reaffirmed a “buy” rating and set a $3.00 target price on shares of ConforMIS in a research report on Thursday, August 2nd. SunTrust Banks reaffirmed a “buy” rating on shares of ConforMIS in a research report on Monday, July 16th. Oppenheimer set a $4.00 target price on ConforMIS and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Finally, ValuEngine upgraded ConforMIS from a “sell” rating to a “hold” rating in a report on Friday, June 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $3.25.
Shares of ConforMIS traded up $0.04, reaching $0.97, during trading hours on Friday, Marketbeat Ratings reports. 167,254 shares of the company’s stock were exchanged, compared to its average volume of 427,072. ConforMIS has a fifty-two week low of $0.88 and a fifty-two week high of $4.17. The firm has a market cap of $58.60 million, a PE ratio of -0.78 and a beta of 0.90. The company has a quick ratio of 4.15, a current ratio of 4.77 and a debt-to-equity ratio of 0.60.
ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings results on Friday, August 3rd. The medical instruments supplier reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). ConforMIS had a negative return on equity of 94.69% and a negative net margin of 64.66%. The business had revenue of $19.10 million for the quarter, compared to analyst estimates of $19.52 million. equities analysts predict that ConforMIS will post -0.83 EPS for the current fiscal year.
ConforMIS Company Profile
ConforMIS, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Article: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.